A detailed history of Black Rock Inc. transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 983,063 shares of AVTE stock, worth $2.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
983,063
Previous 709,752 38.51%
Holding current value
$2.52 Million
Previous $21 Million 92.23%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.41 - $30.75 $385,368 - $8.4 Million
273,311 Added 38.51%
983,063 $1.63 Million
Q1 2024

May 10, 2024

SELL
$17.68 - $29.57 $312,971 - $523,448
-17,702 Reduced 2.43%
709,752 $21 Million
Q4 2023

Feb 13, 2024

BUY
$9.58 - $24.25 $427,967 - $1.08 Million
44,673 Added 6.54%
727,454 $16.5 Million
Q3 2023

Nov 13, 2023

BUY
$12.9 - $18.88 $775,728 - $1.14 Million
60,134 Added 9.66%
682,781 $9.27 Million
Q2 2023

Aug 11, 2023

BUY
$15.63 - $22.01 $353,988 - $498,482
22,648 Added 3.77%
622,647 $10.7 Million
Q1 2023

May 12, 2023

SELL
$19.17 - $27.7 $153,053 - $221,156
-7,984 Reduced 1.31%
599,999 $12.1 Million
Q4 2022

Feb 13, 2023

SELL
$15.92 - $30.52 $1.71 Million - $3.28 Million
-107,462 Reduced 15.02%
607,983 $17.8 Million
Q3 2022

Nov 14, 2022

BUY
$14.77 - $25.79 $148,837 - $259,885
10,077 Added 1.43%
715,445 $11.9 Million
Q2 2022

Aug 12, 2022

SELL
$10.8 - $16.91 $448,912 - $702,881
-41,566 Reduced 5.56%
705,368 $11 Million
Q1 2022

May 12, 2022

BUY
$8.25 - $18.33 $141,289 - $313,919
17,126 Added 2.35%
746,934 $13.7 Million
Q4 2021

Feb 10, 2022

BUY
$9.14 - $21.54 $2.26 Million - $5.32 Million
246,790 Added 51.09%
729,808 $8.61 Million
Q3 2021

Nov 09, 2021

BUY
$11.76 - $22.49 $5.68 Million - $10.9 Million
483,018 New
483,018 $10.1 Million

Others Institutions Holding AVTE

About Aerovate Therapeutics, Inc.


  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $62.6M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.